202 related articles for article (PubMed ID: 32466694)
1. Discovery of secondary sulphonamides as IDO1 inhibitors with potent antitumour effects
Ge S; Zhong H; Ma X; Zheng Y; Zou Y; Wang F; Wang Y; Hu Y; Li Y; Liu W; Guo W; Xu Q; Lai Y
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1240-1257. PubMed ID: 32466694
[TBL] [Abstract][Full Text] [Related]
2. Discovery of imidazoleisoindole derivatives as potent IDO1 inhibitors: Design, synthesis, biological evaluation and computational studies.
Zou Y; Wang F; Wang Y; Sun Q; Hu Y; Li Y; Liu W; Guo W; Huang Z; Zhang Y; Xu Q; Lai Y
Eur J Med Chem; 2017 Nov; 140():293-304. PubMed ID: 28963992
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening.
Sari S; Tomek P; Leung E; Reynisson J
Molecules; 2019 Nov; 24(23):. PubMed ID: 31795096
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors.
Xia Z; Nan Y; Liu C; Lin G; Gu K; Chen C; Zhao W; Ju D; Dong X
Anticancer Agents Med Chem; 2020; 20(13):1592-1603. PubMed ID: 32496990
[TBL] [Abstract][Full Text] [Related]
6. Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form.
Nelp MT; Kates PA; Hunt JT; Newitt JA; Balog A; Maley D; Zhu X; Abell L; Allentoff A; Borzilleri R; Lewis HA; Lin Z; Seitz SP; Yan C; Groves JT
Proc Natl Acad Sci U S A; 2018 Mar; 115(13):3249-3254. PubMed ID: 29531094
[TBL] [Abstract][Full Text] [Related]
7. Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).
Pan S; Zhou Y; Wang Q; Wang Y; Tian C; Wang T; Huang L; Nan J; Li L; Yang S
Eur J Med Chem; 2020 Dec; 207():112703. PubMed ID: 32871341
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent IDO1 inhibitors derived from tryptophan using scaffold-hopping and structure-based design approaches.
Zou Y; Wang Y; Wang F; Luo M; Li Y; Liu W; Huang Z; Zhang Y; Guo W; Xu Q; Lai Y
Eur J Med Chem; 2017 Sep; 138():199-211. PubMed ID: 28667875
[TBL] [Abstract][Full Text] [Related]
9. Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects.
Jiang X; Li X; Zheng S; Du G; Ma J; Zhang L; Wang H; Tian J
Int J Immunopathol Pharmacol; 2020; 34():2058738420950584. PubMed ID: 32962460
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors.
Song X; Sun P; Wang J; Guo W; Wang Y; Meng LH; Liu H
Eur J Med Chem; 2020 Mar; 189():112059. PubMed ID: 31981851
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
Liu X; Shin N; Koblish HK; Yang G; Wang Q; Wang K; Leffet L; Hansbury MJ; Thomas B; Rupar M; Waeltz P; Bowman KJ; Polam P; Sparks RB; Yue EW; Li Y; Wynn R; Fridman JS; Burn TC; Combs AP; Newton RC; Scherle PA
Blood; 2010 Apr; 115(17):3520-30. PubMed ID: 20197554
[TBL] [Abstract][Full Text] [Related]
12. 4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.
Yang L; Chen Y; He J; Njoya EM; Chen J; Liu S; Xie C; Huang W; Wang F; Wang Z; Li Y; Qian S
Bioorg Med Chem; 2019 Mar; 27(6):1087-1098. PubMed ID: 30773421
[TBL] [Abstract][Full Text] [Related]
13. Nitrobenzofurazan derivatives of N'-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1.
Paul S; Roy A; Deka SJ; Panda S; Trivedi V; Manna D
Eur J Med Chem; 2016 Oct; 121():364-375. PubMed ID: 27267006
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of flavonoids isolated from
Kwon M; Ko SK; Jang M; Kim GH; Ryoo IJ; Son S; Ryu HW; Oh SR; Lee WK; Kim BY; Jang JH; Ahn JS
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1481-1488. PubMed ID: 31423846
[TBL] [Abstract][Full Text] [Related]
15. Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents.
Wen H; Liu Y; Wang S; Wang T; Zhang G; Chen X; Li Y; Cui H; Lai F; Sheng L
Molecules; 2019 Jun; 24(11):. PubMed ID: 31195673
[TBL] [Abstract][Full Text] [Related]
16. Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy.
He X; He G; Chu Z; Wu H; Wang J; Ge Y; Shen H; Zhang S; Shan J; Peng K; Wei Z; Zou Y; Xu Y; Zhu Q
J Med Chem; 2021 Dec; 64(24):17950-17968. PubMed ID: 34854662
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the BET family reduces its new target gene IDO1 expression and the production of L-kynurenine.
Tian CQ; Chen L; Chen HD; Huan XJ; Hu JP; Shen JK; Xiong B; Wang YQ; Miao ZH
Cell Death Dis; 2019 Jul; 10(8):557. PubMed ID: 31324754
[TBL] [Abstract][Full Text] [Related]
18. Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer.
Du Q; Feng X; Wang Y; Xu X; Zhang Y; Qu X; Li Z; Bian J
Eur J Med Chem; 2019 Nov; 182():111629. PubMed ID: 31445231
[TBL] [Abstract][Full Text] [Related]
19. Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme.
Hamilton MM; Mseeh F; McAfoos TJ; Leonard PG; Reyna NJ; Harris AL; Xu A; Han M; Soth MJ; Czako B; Theroff JP; Mandal PK; Burke JP; Virgin-Downey B; Petrocchi A; Pfaffinger D; Rogers NE; Parker CA; Yu SS; Jiang Y; Krapp S; Lammens A; Trevitt G; Tremblay MR; Mikule K; Wilcoxen K; Cross JB; Jones P; Marszalek JR; Lewis RT
J Med Chem; 2021 Aug; 64(15):11302-11329. PubMed ID: 34292726
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
